Senesco Technologies, Inc. (“Senesco” or the “Company”) (NYSE AMEX: SNT) announced that the Company will be presenting at the 13 th Annual Rodman & Renshaw Healthcare Conference being held at the Waldorf Astoria in New York City from September 11th – 13th, 2011. Leslie J. Browne, Ph.D., President and CEO of Senesco, will deliver the Company’s corporate presentation and provide an update on its clinical plans on Tuesday, September 13th, at 2:50 p.m. (Eastern Time) in the Metropolitan East room. Senesco recently received approval from the U.S. Food and Drug Administration to begin a Phase 1b/2a clinical study of SNS01-T, the Company’s lead therapeutic candidate for the treatment of multiple myeloma, and has an agreement and IRB approval to perform the study at the Mayo Clinic. The Company will be available for one-on-one meetings with investors participating in the Rodman & Renshaw Healthcare Conference. For those who would like to schedule an appointment with Senesco management, please contact Bob Woods, CEOcast, Inc., at 212-732-4300 or at email@example.com or contact your Rodman & Renshaw representative. The Company’s webcast presentation may be viewed at: http://www.wsw.com/webcast/rrshq20/snt. The webcast will be available for 90 days following the presentation. About Multiple Myeloma Multiple myeloma is an incurable cancer of plasma cells, a type of white blood cell derived from B-lymphocytes, normally responsible for the production of antibodies. Malignant plasma cells accumulate in the bone marrow leading to bone lesions and interfering with the production of normal white blood cells. Median survival time from first treatment is 2½ to 5 years depending on disease stage at diagnosis. In the United States there are approximately 20,000 newly diagnosed cases of multiple myeloma annually and a total of approximately 65,000 patients with the disease. Senesco was previously granted orphan drug status for SNS01-T, the Company’s lead drug candidate for treatment of multiple myeloma.
About Senesco Technologies, Inc.Senesco Technologies is leveraging proprietary technology that regulates programmed cell death, or apoptosis. Accelerating apoptosis may have applications in treating cancer, while delaying apoptosis may have applications treating certain inflammatory and ischemic diseases. The Company is preparing to initiate a clinical study in multiple myeloma with its lead therapeutic candidate SNS01-T. Senesco has already partnered with leading-edge companies engaged in agricultural biotechnology, and is entitled to earn research and development milestones and royalties if its gene-regulating platform technology is incorporated into its partners’ products. Forward-Looking Statements Certain statements included in this press release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from such statements expressed or implied herein as a result of a variety of factors, including, but not limited to: the ability of the Company to consummate additional financings; the development of the Company’s gene technology; the approval of the Company’s patent applications; the successful implementation of the Company’s research and development programs and collaborations; the success of the Company's license agreements; the acceptance by the market of the Company’s products; the timing and success of the Company’s preliminary studies, preclinical research and clinical trials; competition and the timing of projects and trends in future operating performance, the Company’s ability to comply with the continued listing standards of the NYSE Amex, as well as other factors expressed from time to time in the Company’s periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with the Company’s periodic filings with the SEC. The forward-looking statements contained herein are made only as of the date of this press release, and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.